Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gynecologic 2Sarcoma 1Other solid neoplasm 1Genitourinary 1Dermatologic 1

Conditions

Melanoma 43Colorectal Neoplasms 8Uveal Melanoma 5Carcinoma, Renal Cell 5Carcinoma, Non-Small-Cell Lung 5Brain Neoplasms 5Stomach Neoplasms 4Ovarian Neoplasms 4Neoplasm Metastasis 4Lung Neoplasms 3Carcinoma, Merkel Cell 3Squamous Cell Carcinoma of Head and Neck 2Sarcoma 2Pancreatic Neoplasms 2Glioblastoma 2Carcinoma, Hepatocellular 2Waldenstrom Macroglobulinemia 1Uterine Cervical Neoplasms 1Urinary Bladder Neoplasms 1Thyroid Neoplasms 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Prostatic Neoplasms 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Parotid Neoplasms 1Non-Muscle Invasive Bladder Neoplasms 1Neoplasms 1Nasopharyngeal Neoplasms 1Nasopharyngeal Carcinoma 1

Interventions

Taxes 1Immunoglobulin G 1Disulfides 1Bevacizumab 1Albumin-Bound Paclitaxel 1130-nm albumin-bound paclitaxel 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Cervical Adenocarcinoma × Bevacizumab × Dermatologic × Clear all
NCT02020707 2024-07-26

Nab-Paclitaxel and Bevacizumab in Treating Patients With Unresectable Stage IV Melanoma or Gynecological Cancers

Mayo Clinic

Phase 1 Completed
43 enrolled
DermatologicGenitourinaryGynecologicOther solid neoplasmSarcoma

Cervical Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡